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A solid form of esteriﬁed propoxylated glycerol (EPG) was administered to 16 healthy male volunteers in
butter-like spread and baked goods, resulting in intakes that rose in 30-g increments from 30 to 150 g;
each level was administered on a single day, followed by a 2-day washout period. Elevated serum
transaminase (ALT and/or AST) and lower HDL cholesterol levels were noted at 60 g and greater, possibly
related to changes in the diet (high-carbohydrate and increasingly low-fat), rather than to EPG itself.
There was no apparent association between EPG consumption and adverse effects reported. In general,
EPG had no effect on bowel function, except in a single subject, who reported increased frequency of
movements during the 2 days that followed consumption of 150 g EPG. All abnormal values returned to
normal after the study, and subjects were otherwise asymptomatic. Accordingly, the effects on trans-
aminase and HDL levels observed in this study were considered possibly adaptive and not clinically
signiﬁcant. Experimental animal studies, including lifetime studies, had shown no effects on these pa-
rameters. More importantly, the effect was associated with intakes of 60e150 g EPG, which exceeds the
approximate intake of 20 g/day or less expected from currently intended commercial food uses.
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Esteriﬁed propoxylated glycerols (EPGs) are modiﬁed tri-
glycerides, sterically blocked to prevent hydrolysis by pancreatic
lipase. This results in a compound that is protected from digestion
and therefore minimally absorbed.
A series of articles examining the non-clinical and clinical safety
of esteriﬁed propoxylated glycerols (EPGs) was recently published
(Bechtel, 2014a, 2014b; Christian and Bechtel, 2014; Davidson and
Bechtel, 2014; Tyl and Bechtel, 2014a, 2014b; Wedig and Bechtel,
2014). Part of the series included an 8-week study in which hu-
man volunteers received a solid form of EPG at levels up to 40 g per
day in a butter-like spread and in baked goods (Davidson and
Bechtel, 2014). The current article presents the ﬁndings of a sepa-
rate study in which human volunteers received EPG in a similar
way, but at concentrations that increased over time from 30 to
150 g.Davidson Avenue, Suite 102,
Inc. This is an open access article u2. Materials and methods
2.1. Study design
The study was sponsored by ARCO Chemical Company (New-
town Square, PA, USA) and Best Foods (Somerset, NJ, USA), and
conducted at Inveresk Clinical Research (Edinburgh, Scotland) in
1992 as a single-center, domiciled, single-blind study. Prior to
enrollment, each subject underwent screening, including medical
history, physical exam with routine blood and urine analyses, and
electrocardiogram (ECG); informed consent was obtained. Inclu-
sion/exclusion criteria were: healthy males; age 18e50 years; ±20%
of ideal body weight; no prescription medication; no history of
gastrointestinal disease/disorder; no clinically signiﬁcant abnormal
laboratory result; no substance addiction (20 cigarettes/day).
Sixteen healthy male volunteers completed the study. Subjects
were domiciled for a period of 21 days, including 3 pre-study
adaptation days, and 3 days during which foods items containing
only ordinary triglycerides were administered. Subjects received
deﬁned amounts of EPG incorporated into food products over the
course of a given day in a rising-concentration scheme, with a 2-
day washout period in between, as illustrated in Table 1.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Total EPG (g) administered to subjects each day during the study.
Study day
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
0 0 0 0 0 0 0 30 0 0 60 0 0 90 0 0 120 0 0 150 0 0
D.H. Bechtel / Regulatory Toxicology and Pharmacology 73 (2015) 413e4184142.2. Test material
The form of EPG tested was a solid form, H-EPG-05 HR/SO 9:1,
incorporated into bakery items and a butter-like spread. The test
materials were provided by the sponsors as components of dietary
items appropriate for breakfast, lunch, dinner, and snacks. The test
food items (containing ordinary triglycerides and/or EPG) were
cinnamon buns, biscuits, cookies, and butter-like spread. All test
food items were unit-packaged by study subject number, and
labeled such that study subjects remained blinded.
As Table 2 illustrates, EPG replaced more of the dietary fat as the
study progressed. This was accomplished by progressively replac-
ing test food items containing only ordinary triglycerides with test
food items containing EPG.
2.3. Measures
Vital signs (blood pressure, pulse, respiration, body tempera-
ture) were measured daily. Gastrointestinal symptoms, bowel
movement patterns, and adverse events were assessed daily. Serum
chemistry, hematology, and urinalysis (pH, speciﬁc gravity, ketones,
protein, glucose, bilirubin, blood, leukocytes, WBC count, red blood
cell count, and microscopic examination of sediment) were per-
formed the day after EPG consumption.
2.4. Statistical analysis
Due to the small sample size, descriptive statistics were used to
summarize adverse events, general GI symptoms, and bowel
movement patterns. The number of subjects reporting events
(incidence rate) daily and the total number of reported events were
summarized. Laboratory evaluations were summarized by day to
assess mean changes from baseline.
3. Results
3.1. EPG consumption
The calculated EPG intake for the nominal concentrations of 30,
60, 90, 120, and 150 g were 31.1, 61.2, 91.6, 119.7, and 149 g,
respectively.
3.2. Physical exam, vital signs, ECG
There was a mean increase in body weight of 1.7 kg
(range: 0.6e3.9 kg) over the course of the study. All vital signTable 2
Total EPG and fat consumption.
Study day
4 7 10 13 16 19
Nominal EPG (g) 0 30 60 90 120 150
Actual EPG (g) 0 31.1 61.2 91.6 119.7 149.0
Total fat (g)a 301.6 269.7 239.4 208.4 182.9 148.9
a Includes fat from test foods and other food items.measures were within normal limits and no abnormal trends were
noted. All ECG ﬁndings were within the normal limits, except for
one subject, who displayed a prolonged QRS interval (0.126 s) at the
end of the study (Day 22). The principal investigator did not
consider this ﬁnding to be clinically signiﬁcant or related to the test
substance.3.3. Hematology
Mean hematology values, all of which were within the normal
range, are summarized in Table 3. On an individual-subject basis
(data not shown), all Hb, MCH, MCV, and basophil values were
within the normal range. Values for the remaining hematological
parameters were occasionally slightly above or below the normal
range. Slightly greater LUC (large unclassiﬁed cell) levels
(0.21e0.31  109/L vs. normal range of 0e0.2  109/L) were
observed once in each of 8 subjects (4 after 90 g; 1 each after 120 g
and 150 g; and 2 on the second day after 150 g).3.4. Clinical chemistry
Mean clinical chemistry values, summarized in Table 4, were
within the normal range for all parameters, except ALT, bicarbonate,
and HDL cholesterol. However, there was evidence of high bicar-
bonate levels before consumption of EPG (i.e., at screening andwith
0 g EPG).
Mean ALT levels were greater than normal (i.e., >40 IU/L) after
consumption of 60e150 g EPG; at 30 g ALT levels were greater
than prior to EPG consumption, but remained within the normal
range.
Mean HDL cholesterol levels were normal at screening, but
below normal at all other time points, including after consump-
tion of test food items containing only ordinary triglycerides (0 g
EPG).
On an individual-subject basis (data not shown), all values
were within the normal range for BUN, Na, Cl, globulin, A/G ratio,
Ca, and total bilirubin. With the possible exception of AST, ALT,
and HDL cholesterol, all abnormal values were considered un-
related to EPG. The highest ALT and AST level after EPG con-
sumption was 3 times greater than normal; the lowest HDL level
was approximately 30% below the lowest end of the normal
range.3.5. Urinalysis
Mean urine speciﬁc gravity and pH values are listed in Table 5.
Traces of protein, glucose, or bilirubin in the urine were seen oc-
casionally, but the ﬁndings were not considered by the principal
investigator to be clinically signiﬁcant; in some instances, repeat
analysis showed negative results. One subject (# 8) had traces of
red blood cells in the urine at various times, but the principal
investigator did not consider this to be related to the study
material.
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The majority of adverse events reported was related to gastro-
intestinal symptoms and occurred on the days the test foods were
consumed (Table 6). None appeared to be related to EPG con-
sumption per se, although reports of ﬂatulence (number of times
reported and number of subjects) occurred more frequently with
EPG vs. ordinary triglycerides (0 g EPG).
No serious adverse events were reported. The only
unusual symptoms reported were anal pain in Subject # 1 and
blood in the stool of Subject # 4. In Subject # 1, the effect was
considered related to irritation due to frequent bowel move-
ments following consumption of 150 g EPG (see Bowel Function
section). Subject # 4, who reported passage of blood in the stool
following consumption of 150 g EPG, was found to have a small
anal tear.
3.7. Bowel function
As Table 7 illustrates, bowel movements (total bowel move-
ments) were most frequent on days the test foods were adminis-
tered. In general, EPG intake was associated with a shift toward a
greater number of movements rated as “formed but soft” vs.
“formed but hard,” but there was no consistent association with
EPG concentration.
Aside from being asked questions about the number of bowel
movements, appearance, and discomfort (e.g., pain, straining and
cramping), subjects were asked if there was anything unusual
about the stool appearance and, if so, to provide a description. As
Table 7 shows, there was no apparent relationship between EPG
concentration and the number of bowel movements rated by
subjects as “unusual,” with the possible exception of Subject # 1,
who reported a total of 10 “unusual” movements during the 2 days
that followed consumption of 150 g EPG; the movements were
described as “loose” with “white particles” or “oil on surface of
water.” All other “unusual” movements that occurred following
administration of EPGwere seen only with 30 g and/or 60 g, but not
thereafter, or with 30, 90, and 150 g, but not 60 or 120 g “Unusual”
movements were also seen following administration of margarine
alone (0 g EPG).
4. Discussion
Dietary concentrations of EPG ranging from 30 to 150 g had no
apparent effect on vital signs. Body weights increased slightly
during the study, possibly due to greater consumption of carbo-
hydrates from the test foods. Some variations in hematology, clin-
ical chemistry, and urinalysis parameters were observed. However,
most deviations from normal were not considered clinically sig-
niﬁcant or related to EPG, by virtue of: (1) being only slightly higher
or lower than normal; (2) also being present prior to EPG exposure;
and/or (3) occurring sporadically, with no evidence of a relation-
ship to EPG concentration.
Higher than normal serum transaminase (ALT and/or AST)
levels were seen in some subjects at 60e150 g EPG. ALT and AST
are markers of liver injury, but there are other non-hepatic
causes of elevated ALT and AST, such as celiac disease, hypo-
and hyperthyroidism, and strenuous exercise (reviewed by
Dancygier and Rogart, 2010). These are unlikely to have been the
cause of elevated ALT and AST in our study. However, Purkins
et al. (2003) reported ALT and AST levels 1.5e2 times the
normal values in a study of a study population similar to ours, 12
healthy men aged 20e41 years residing at a study facility,
following consumption of a high-carbohydrate high-calorie diet
for 8 days. Speciﬁcally, the rises in transaminase levels were
Table 4
Mean clinical chemistry values among subjects receiving increasing EPG concentrations in the diet.
Time
period
EPG
concentration
BUN
(mmol/L)
Glu
(mmol/L)
AST
(IU/L)
ALT
(IU/L)
AP
(IU/L)
LDH
(IU/L)
Na
(mmol/L)
K
(mmol/L)
Cl
(mmol/L)
Ca
(mmol/L)
Phos
(mmol/L)
Bic
(mmol/L)
Pre-study None 4.6 ± 0.9 4.92 ± 0.49 18 ± 3 20 ± 7 162 ± 40 292 ± 73 139 ± 1 3.8 ± 0.3 105 ± 2 2.36 ± 0.09 0.94 ± 0.13 31 ± 5
Day 5 0 ga 4.1 ± 0.9 5.59 ± 0.31 26 ± 12 26 ± 11 156 ± 40 421 ± 140 141 ± 1 4.2 ± 0.3 106 ± 2 2.27 ± 0.09 1.04 ± 0.16 30 ± 2
Day 8 30 g 4.3 ± 0.9 4.50 ± 0.34 28 ± 19 35 ± 23 155 ± 39 284 ± 54 141 ± 1 3.9 ± 0.3 105 ± 2 2.31 ± 0.07 0.92 ± 0.15 27 ± 3
Day 11 60 g 4.4 ± 0.9 4.77 ± 0.33 31 ± 11 46 ± 28 162 ± 35 269 ± 41 139 ± 1 3.9 ± 0.3 105 ± 2 2.19 ± 0.05 0.93 ± 0.13 27 ± 2
Day 14 90 g 4.6 ± 0.7 4.69 ± 0.46 29 ± 13 48 ± 23 167 ± 39 281 ± 68 141 ± 1 4.0 ± 0.2 106 ± 2 2.28 ± 0.06 0.95 ± 0.13 28 ± 2
Day 17 120 g 4.9 ± 0.8 4.09 ± 0.57 27 ± 9 45 ± 19 173 ± 38 281 ± 33 140 ± 2 3.9 ± 0.3 104 ± 2 2.23 ± 0.07 0.92 ± 0.17 30 ± 2
Day 20 150 g 4.9 ± 0.9 4.35 ± 0.43 23 ± 9 43 ± 22 179 ± 40 285 ± 61 138 ± 1 3.9 ± 0.4 104 ± 1 2.27 ± 0.07 0.93 ± 0.14 31 ± 2
Day 22 None 4.4 ± 0.8 4.68 ± 0.43 28 ± 12 42 ± 18 178 ± 41 286 ± 49 141 ± 2 4.1 ± 0.3 105 ± 1 2.32 ± 0.08 0.88 ± 0.13 29 ± 2
Normal
range
1.7e8.3 4.22e6.11 <37 <40 98e279 230e460 135e150 3.3e4.8 99e109 2.02e2.60 0.87e1.45 23e29
Time period EPG
concentration
Creat
(mmol/L)
T. Bil
(mmol/L)
Uric
(mmol/L)
TP
(g/L)
Alb
(g/L)
Glob
(g/L)
A/G Chol
(mmol/L)
Trig
(mmol/L)
HDL
(mmol/L)
LDL
(mmol/L)
Pre-study None 94 ± 10 9.6 ± 3.8 325 ± 67 73 ± 2 46 ± 3 27 ± 2 1.8 ± 0.2 5.4 ± 0.9 1.64 ± 0.63 1.09 ± 0.18 3.58 ± 0.88
Day 5 0 ga 95 ± 8 6.2 ± 2.3 300 ± 59 68 ± 3 45 ± 2 23 ± 2 2.0 ± 0.1 4.8 ± 0.7 1.28 ± 0.39 0.88 ± 0.17 3.53 ± 0.78
Day 8 30 g 87 ± 5 6.9 ± 1.9 299 ± 59 67 ± 3 42 ± 2 25 ± 3 1.7 ± 0.2 4.6 ± 0.7 1.60 ± 0.48 0.95 ± 0.16 2.83 ± 0.69
Day 11 60 g 89 ± 7 6.1 ± 1.4 303 ± 64 69 ± 2 44 ± 2 24 ± 2 1.8 ± 0.2 4.9 ± 0.8 1.57 ± 0.41 0.83 ± 0.17 3.73 ± 0.86
Day 14 90 g 87 ± 6 6.7 ± 1.5 318 ± 59 69 ± 3 44 ± 2 26 ± 3 1.7 ± 0.2 5.1 ± 0.9 1.81 ± 0.58 0.90 ± 0.13 3.35 ± 0.67
Day 17 120 g 87 ± 8 7.5 ± 1.7 325 ± 61 69 ± 2 43 ± 2 26 ± 3 1.7 ± 0.2 5.1 ± 0.9 1.75 ± 0.51 0.74 ± 0.10 3.48 ± 0.74
Day 20 150 g 89 ± 6 8.5 ± 2.3 328 ± 61 69 ± 2 44 ± 2 25 ± 2 1.7 ± 0.2 5.1 ± 0.9 2.07 ± 0.61 0.75 ± 0.22 3.47 ± 0.69
Day 22 None 88 ± 7 9.3 ± 3.0 320 ± 60 71 ± 3 44 ± 2 27 ± 3 1.7 ± 0.2 5.2 ± 0.9 2.01 ± 0.54 0.72 ± 0.14 3.70 ± 0.66
Normal range 82e106 <17.0 202e416 66e87 43e53 16e38 0.9e2.8 3.2e6.8 <2.28 0.9e1.43 <3.9
Values represent the mean ± SD for 16 subjects.
BUN: blood urea nitrogen; Glu: glucose; AST: aspartate aminotransferase; ALT: alanine aminotransferase; AP: alkaline phosphatase; LDH: lactate dehydrogenase; Na: sodium;
K: potassium; Cl: chloride; Ca: calcium; Phos: inorganic phosphate; Bic: bicarbonate.
Creat: creatinine; T. Bil: total bilirubin; Uric: uric acid; TP: total protein; Alb: albumin; Glob: globulin; A/G: albumin/globulin ratio; Chol: total cholesterol; Trig: triglycerides;
HDL: high-density lipoprotein; LDL: low-density lipoprotein.
a Test food items prepared with ordinary triglycerides (margarine) alone.
D.H. Bechtel / Regulatory Toxicology and Pharmacology 73 (2015) 413e418416considered related to the carbohydrate content of the diet,
especially sucrose, rather than its caloriﬁc value. Porikos and Van
Itallie (1983) also reported transient elevations in ALT and AST
levels in 21 male subjects receiving a hypercaloric high-sucrose
diet for 18 days while housed in a metabolic ward. It is there-
fore possible that the elevated transaminase levels seen in this
study were related to a higher intake of simple sugars from the
test food items (cinnamon buns, biscuits, cookies), rather than to
EPG intake.
Along with a number of conditions (e.g., diabetes and end-stage
renal disease) and agents (beta-blockers and thiazide diuretics),
low-fat diets can result in reduced HDL cholesterol levels (Rader,
2007). This might account for the serum HDL decline of subjects
in this study. Indeed, EPG gradually replaced (i.e., reduced) up to
half the available fat in the diet; at 150 g EPG, all subjects showed
lower than normal HDL cholesterol values (data not shown).Table 5
Mean urine speciﬁc gravity and pH values among subjects receiving increasing EPG
concentrations in the diet.
Time period EPG concentration Speciﬁc gravity pH
Pre-study None 1.0209 ± 0.0081 5.71 ± 0.66
Day 5 0 ga 1.0228 ± 0.0066 5.91 ± 0.61
Day 8 30 g 1.0256 ± 0.0048 5.66 ± 0.63
Day 11 60 g 1.0238 ± 0.0056 5.78 ± 0.60
Day 14 90 g 1.0225 ± 0.0063 5.75 ± 0.55
Day 17 120 g 1.0238 ± 0.0062 5.47 ± 0.56
Day 20 150 g 1.0172 ± 0.0055 6.13 ± 0.34
Day 22 None 1.0206 ± 0.0073 5.50 ± 0.61
Values represent the mean ± SD for 16 subjects, except pre-study, which included
17 subjects.
a Test food items prepared with ordinary triglycerides (margarine) alone.Because all abnormal values returned to normal after the study,
and subjects were otherwise asymptomatic, the effects on trans-
aminase and HDL levels observed in this study were considered
possibly adaptive and not clinically signiﬁcant. Other safety studies
of EPG, including lifetime experimental animal studies, showed no
effects on these transaminase or HDL levels.
There was no apparent association between EPG consumption
and adverse effects reported. Most adverse events consisted of
gastrointestinal symptoms and were reported on the days the test
foods were consumed (vs. the 2 days that followed), suggesting it
was related to the large volume of food consumed. Indeed, themost
frequently reported adverse effect, reported on 20 occasions by
nearly all (15/16) subjects, was bloating/fullness after consumption
of test foods containing only ordinary triglycerides (0 g EPG).
Flatulence was reported with greater frequency when subjects
consumed EPG, but the incidence did not increase with increasing
EPG concentration.
In general, EPG had no apparent effect on bowel function, except
in a single subject, who reported increased frequency of move-
ments during the 2 days that followed consumption of 150 g EPG.
Bowel movements were most frequent on days the test foods were
administered, probably related to the volume of food, rather than
EPG, since the effect was also evident following consumption of
foods without EPG (0 g). There was a shift toward “well-formed but
soft” stool with EPG, but with no apparent relation to EPG
concentration.
The results of this study indicate that intakes of up to 150 g EPG
in a single day were safe and well tolerated by nearly all subjects.
Based on this and the results of other studies, human dietary ex-
posures of up to 20 g EPG/day from its currently intended com-
mercial use as a fat substitute would not be expected to result in
any adverse health effects.
Table 6
Adverse events reported by subjects receiving increasing EPG concentrations in the diet.
EPG
concentration
Time period Belching/
burping
Flatulence Bloating/
fullness
Heartburn Nausea Vomiting Abdominal
pain
Other,
non-GI
Difﬁculty
swallowing
Anal
pain
Oil in
bowel
motions
Abnormal
bowel motion but
presence of oil not
recorded
0 ga Day administered 2 (2) 4 (4) 20 (15) 2 (2) 15 (9) 3 (3) 2 (2) 0 7 (7) 0 0 0
1 Day after 2 (2) 1 (1) 2 (2) 3 (3) 0 0 2 (2) 4 (4) 0 0 0 0
2 Days after 1 (1) 2 (2) 2 (2) 0 0 0 2 (2) 0 0 0 0 1 (1)
30 g Day administered 5 (5) 8 (8) 13 (12) 2 (2) 10 (9) 4 (2) 3 (3) 2 (2) 15 (7) 0 0 2 (2)
1 Day after 1 (1) 1 (1) 1 (1) 1 (1) 0 0 3 (1) 5 (5) 0 0 0 1 (1)
2 Days after 0 0 0 0 0 0 0 0 0 0 0 0
60 g Day administered 2 (2) 7 (7) 9 (8) 0 6 (6) 0 4 (4) 1 (1) 15 (6) 0 1 (1) 1 (1)
1 Day after 0 0 0 1 (1) 0 0 0 4 (3) 0 0 0 0
2 Days after 0 0 0 0 0 0 0 3 (2) 0 0 0 0
90 g Day administered 3 (3) 9 (9) 13 (9) 0 0 0 6 (4) 2 (2) 8 (2) 0 0 0
1 Day after 0 1 (1) 0 0 0 0 4 (3) 4 (4) 0 0 0 0
2 Days after 0 0 0 0 0 0 1 (1) 4 (4) 0 0 0 0
120 g Day administered 2 (2) 6 (6) 4 (4) 0 0 0 2 (2) 4 (3) 4 (4) 0 0 1 (1)
1 Day after 1 (1) 3 (3) 0 0 0 0 1 (1) 1 (1) 0 0 0 0
2 Days after 0 1 (1) 1 (1) 0 0 0 0 0 0 0 0 2 (2)
150 g Day administered 2 (2) 11 (11) 7 (7) 0 0 0 2 (2) 1 (1) 1 (1) 0 0 1 (1)
1 Day after 0 2 (2) 1 (1) 0 0 0 3 (3) 1 (1) 0 1 (1) 0 1 (1)
2 Days after 0 3 (3) 0 0 0 0 0 1 (1) 0 0 0 0
Each set of values represents the number of times the adverse event was reported with the number of subjects reporting the event in parentheses; 16 subjects completed the
study.
a Test food items prepared with ordinary triglycerides (margarine) alone.
Table 7
Summary of bowel movement characterization.
EPG
concentration
Time period Total bowel
movements
Description Total movements
rated as “unusual”c
Formed
but hard
Formed
but soft
Poorly
formed,
loose
Loose,
watery
Containing
mucus
Pain-free Painful Accompanied by
straining or cramping
None Pre-study 16 9 7 0 0 0 16 0 0 0
Pre-study 22 10 12 0 0 0 22 0 0 0
Pre-study 22 3 19 0 0 0 22 0 0 0
0 ga Day administered 36 13 18 5 0 0 36 0 0 4
1 Day after 20 6 12 2 0 0 20 0 0 3
2 Days after 27 8 15 4 0 0 26 1 0 3
30 g Day administered 44 2 29 9 4 0 42 0 2 7
1 Day after 29 1 23 5 0 0 27 0 2 4
2 Days after 24 2 19 3 0 0 24 0 0 2
60 g Day administered 35 3 29 3 0 0 35 0 0 3
1 Day after 25 2 21 2 0 0 25 0 0 0
2 Days after 22 4 18 0 0 0 22 0 0 0
90 g Day administered 33 2 30 1 0 0 33 0 0 0
1 Day after 32 8 21 3 0 0 32 0 0 4
2 Days after 16 2 14 0 0 0 16 0 0 0
120 g Day administered 37 6 29 2 0 0 37 0 0 3
1 Day after 26 1 22 3 0 0 26 0 0 1
2 Days after 21 3 16 2 0 0 21 0 0 1
150 g Day administered 43 4 37 2 0 0 42 1 0 1
1 Day after 40 2 24 6 8 0 24 8 8 10b
2 Days after 20 2 17 1 0 0 20 0 0 1
Values represent the totals reported by 16 subjects.
a Test food items prepared with ordinary triglycerides (margarine) alone.
b Subject# 1 had 10 “unusual” bowel movements after consuming 150 g EPG, 9 occurring 1 day after and 1 occurring 2 days after.
c Bowel movements might also have been classiﬁed as “unusual,” with details such as “very pale in color” and/or “foul smelling.” This classiﬁcation would have been
separate from the categories under Description in this table.
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